SUBSCRIBE
SUBSCRIBE

Elizabeth Glasure

Business
BioSpace Feature: A Look at Miracle Drug Humira’s Journey to Proven Efficacy
“Humira is an anti-TNF monoclonal antibody that currently treats Crohn’s disease, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis and uveitis,” quotes Humira developer AbbVie’s website. Those, plus other unlisted ailments, total at 15 conditions treated by only one drug.
December 4, 2018
 · 
4 min read
 · 
Elizabeth Glasure
Business
Small Hospitals Partner With Large Drug Companies for Mutual Benefits
When drug trials are mentioned, mental dots are connected to large hospitals first, with names like the Cleveland Clinic, the Mayo Clinic, or New York Presbyterian Hospital coming to mind. Often overlooked, however, are smaller regional hospitals, important players in the total research picture that are rarely acknowledged as contributors in the information game.
November 19, 2018
 · 
4 min read
 · 
Elizabeth Glasure
Business
New Study Concludes That Genetic Testing Is Not as Final as We Thought
Genetic testing has become an important medical standard for families with known histories of hereditary disease. Individuals who choose to go through the mental and emotional process of taking a genetic test and absorbing the potentially life-changing conclusions may be disturbed to find out that results of such tests are not always consistent.
October 29, 2018
 · 
4 min read
 · 
Elizabeth Glasure
Voyager Sinks as Sanofi Genzyme Opts Out of Parki
Business
Evotec and Sanofi Join to Further Cutting-Edge Therapeutic Drug Discovery
Yesterday, Evotec AG (EVT) announced that Sanofi will be participating in an organized Public Private Partnership (PPP) that involves the initiation of brand newly formed BRIDGE, or LAB031, which was created to further the discovery of therapeutic drugs in multiple areas.
October 5, 2018
 · 
3 min read
 · 
Elizabeth Glasure
Courtesy josefkubes/Getty Images_John Reed_courtes
Business
Arrowhead Goes All in With J&J to Develop Hep B Drug for $3.7B
Arrowhead announced a deal with Johnson & Johnson that could conceivably be worth over $3.7 billion, with J&J agreeing to pick up a minor stake in the company, including the task of cultivating and promoting its ARO-HBV Hepatitis B drug.
October 4, 2018
 · 
3 min read
 · 
Elizabeth Glasure
Drug Development
Bionomics Announces that BNC210 Doesn’t Treat PTSD Symptoms
Yesterday, top-line data from Bionomics Limited revealed details of the biopharmaceutical company’s Phase II clinical trial of BNC210 in regards to patients with post traumatic stress disorder.
October 3, 2018
 · 
3 min read
 · 
Elizabeth Glasure
Business
Synlogic Names Aoife Brennan as President and CEO
Synlogic, Inc. (Nasdaq: SYBX), a biology-focused clinical-stage company focused on living medicines, has just today announced that effective immediately, Aoife Brennan, M.B., B.Ch., has been appointed as president and chief executive officer (CEO).
October 2, 2018
 · 
3 min read
 · 
Elizabeth Glasure
Genetown
KSQ Gains $80 Million Series C Financing for CRISPRomics Development
Just this morning, KSQ Therapeutics disclosed that they’ve obtained an $80 million Series C financing that will be put towards the development of oncology drug candidates via CRISPRomics™, a drug discovery engine that creates insights specific to individual human genes on an industrial scale.
September 28, 2018
 · 
3 min read
 · 
Elizabeth Glasure
Drug Development
Alnylam Indicates Phase III Trial Is Successful Thus Far
Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) in presently in the midst of a Phase 3 study of givosiran, reporting that the drug has been successful in a clinical trial. The company hopes to use their trial data in getting givosiran approved by the U.S. Food and Drug Administration (FDA).
September 27, 2018
 · 
3 min read
 · 
Elizabeth Glasure
Deals
Alexion to Obtain Syntimmune for $400M up Front
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune have just today announced that Alexion will be acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn).
September 26, 2018
 · 
3 min read
 · 
Elizabeth Glasure
Business
$80 Million Series B Financing Funds Morphic Therapeutic’s Next-Generation Oral Integrin
Biotechnology company Morphic Therapeutic has just publicized their completion of a successful $80 million Series B financing meant to support their two lead programs in developing modern oral integrin therapies, as well as further other clinic programs.
September 25, 2018
 · 
3 min read
 · 
Elizabeth Glasure
Drug Development
Epizyme Announces Removal of FDA’s Partial Ban in Phase II Clinical Trials
Epizyme, an innovative epigenetic therapy development company, announced this morning that the U.S. Food and Drug Administration has removed their former partial clinical hold reported in April of this year.
September 24, 2018
 · 
3 min read
 · 
Elizabeth Glasure
Load More